Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model

Vaccine

Volumn 28, Issue 18, 2010, Pages 3071-3075

  Whaley, Melissa J ^a   Sampson, Jacquelyn S ^a   Johnson, Scott E ^a   Rajam, Gowrisankar ^a   Stinson Parks, Annie ^a   Holder, Patricia ^a   Mauro, Erica ^a   Romero Steiner, Sandra ^a   Carlone, George M ^a   Ades, Edwin W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Expanded vaccine coverage; Non interference; Pneumococcal vaccines

Indexed keywords

IMMUNOGLOBULIN G; PNEUMOCOCCAL SURFACE ADHESIN A; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NASOPHARYNX; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; VACCINE PRODUCTION;

ADHESINS, BACTERIAL; ANIMALS; ANTIBODIES, BACTERIAL; CARRIER STATE; LIPOPROTEINS; MICE; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VACCINES, COMBINED;

EID: 77949658166     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.086     Document Type: Article

References (61)

1. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 18 (2003) 1737-1746
2. Hicks LauriA, Harrison LeeH, Flannery B., Hadler JamesL, Schaffner W., Craig AllenS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 196 9 (2007) 1346-1354
3. Hanage W.P. Serotype replacement in invasive pneumococcal disease: where do we go from here?. J Infect Dis 196 9 (2007) 1282-1284
4. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 5 3 (1999) 336-345
5. Pelton S.I., Huot H., Finkelstein J.A., Bishop C.J., Hsu K.K., Kellenberg J., et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 26 6 (2007) 468-472
6. Messina A.F., Katz-Gaynor K., Barton T., Ahmad N., Ghaffar F., Rasko D., et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 26 6 (2007) 461-467
7. Jacobs M.R., Good C.E., Beall B., Bajaksouzian S., Windau A.R., and Whitney C.G. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J Clin Microbiol 46 3 (2008) 982-990
8. Choi E.H., Kim S.H., Eun B.W., Kim S.J., Kim N.H., Lee J., et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 14 2 (2008) 275-281
9. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 16 (2007) 1784-1792
10. Pai R., Moore M.R., Pilishvili T., Gertz R.E., Whitney C.G., and Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192 11 (2005) 1988-1995
11. Moore M.R., and Whitney C.G. Editorial commentary: emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect?. Clin Infect Dis 46 2 (2008) 183-185
12. Cutts F.T., Zaman S.M.A., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 9465 (2005) 1139-1146
13. Scott D., Ruckle J., Dar M., Baker S., Kondoh H., and Lockhart S. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr Int 50 3 (2008) 295-299
14. Barocchi M.A., Censini S., and Rappuoli R. Vaccines in the era of genomics: the pneumococcal challenge. Vaccine 25 16 (2007) 2963-2973
15. Steinhoff M.C. Animal models for protein pneumococcal vaccine evaluation: a summary. Vaccine 25 13 (2007) 2465-2470
16. Briles D.E., Ades E., Paton J.C., Sampson J.S., Carlone G.M., Huebner R.C., et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68 2 (2000) 796-800
17. Talkington D.F., Brown B.G., Tharpe J.A., Koenig A., and Russell H. Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb Pathog 21 1 (1996) 17-22
18. Johnson S.E., Dykes J.K., Jue D.L., Sampson J.S., Carlone G.M., and Ades E.W. Inhibition of pneumococcal carriage in mice by subcutaneous immunization with peptides from the common surface protein pneumococcal surface adhesin A. J Infect Dis 185 4 (2002) 489-496
19. Briles D.E., Hollingshead S.K., Paton J.C., Ades E.W., Novak L., van Ginkel F.W., et al. Immunizations with pneumococcal surface protein a and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 188 3 (2003) 339-348
20. Tai S.S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 32 3 (2006) 139-153
21. Hamel J., Charland N., Pineau I., Ouellet C., Rioux S., Martin D., et al. Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 72 5 (2004) 2659-2670
22. Ogunniyi A.D., Grabowicz M., Briles D.E., Cook J., and Paton J.C. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 75 1 (2007) 350-357
23. Johnson S.E., Rubin L., Romero-Steiner S., Dykes J.K., Pais L.B., Rizvi A., et al. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J Infect Dis 180 1 (1999) 133-140
24. Rajam G., Jackson D., Pilishvili T., Whitney C.G., Facklam R.R., Carlone G.M., et al. An in vitro model to assess pneumococcal adherence to nasopharyngeal cells under competition conditions. J Microbiol Methods 70 2 (2007) 219-226
25. Weiser J.N., Austrian R., Sreenivasan P.K., and Masure H.R. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect Immun 62 6 (1994) 2582-2589
26. Moreno R.L., Sampson J.S., Romero-Steiner S., Wong B., Johnson S.E., Ades E., et al. A murine model for the study of immune memory in response to pneumococcal conjugate vaccination. Vaccine 22 23-24 (2004) 3069-3079
27. Tharpe J.A., Russell H., Leinonen M., Plikaytis B.D., Breiman R.F., Carlone G.M., et al. Comparison of a pneumococcal common protein (PsaA) antibody ELISA and a PsaA immune complex ELISA for detection of pneumococcal serum antibody. Pathobiology 66 2 (1998) 77-83
28. Crook J., Tharpe J.A., Johnson S.E., Williams D.B., Stinson A.R., Facklam R.R., et al. Immunoreactivity of five monoclonal antibodies against the 37-kilodalton common cell wall protein (PsaA) of Streptococcus pneumoniae. Clin Diagn Lab Immunol 5 2 (1998) 205-210
29. Concepcion N.F., and Frasch C.E. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 8 2 (2001) 266-272
30. Plikaytis B.D., Goldblatt D., Frasch C.E., Blondeau C., Bybel M.J., Giebink G.S., et al. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol 38 6 (2000) 2043-2050
31. Romero-Steiner S., Libutti D., Pais L.B., Dykes J., Anderson P., Whitin J.C., et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4 4 (1997) 415-422
32. Romero-Steiner S., Frasch C.E., Carlone G., Fleck R.A., Goldblatt D., and Nahm M.H. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 13 2 (2006) 165-169
33. Isoda R., Robinette R.A., Pinder T.L., McArthur W.P., and Brady L.J. Basis of beneficial immunomodulation by monoclonal antibodies against Streptococcus mutans adhesin P1. FEMS Immunol Med Microbiol 51 1 (2007) 102-111
34. Fabrizio K., Groner A., Boes M., and Pirofski L.-a. A human monoclonal immunoglobulin m reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection. Clin Vaccine Immunol 14 4 (2007) 382-390
35. Wu H.-Y., Virolainen A., Mathews B., King J., Russell M.W., and Briles D.E. Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathog 23 3 (1997) 127-137
36. Briles D.E., Hollingshead S.K., Nabors G.S., Paton J.C., and Brooks-Walter A. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 19 Supplement 1 (2000) S87-S95
37. Cao J., Chen D., Xu W., Chen T., Xu S., Luo J., et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Vaccine 25 27 (2007) 4996-5005
38. Bogaert D., De Groot R., and Hermans P.W.M. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4 3 (2004) 144-154
39. Chávez-Bueno S., and McCracken G.H. Bacterial meningitis in children. Pediatr Clin North Am 52 3 (2005) 795-810 vii
40. Dagan R., Givon-Lavi N., Fraser D., Lipsitch M., Siber G.R., and Kohberger R. Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis 192 3 (2005) 367-376
41. Millar E.V., O'Brien K.L., Bronsdon M.A., Madore D., Hackell J.G., Reid R., et al. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 44 9 (2007) 1173-1179
42. Dagan R., and Klugman K.P. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 8 12 (2008) 785-795
43. Yu X., Gray B., Chang S-j, Ward J.I., Edwards K.M., and Nahm M.H. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis 180 5 (1999) 1569-1576
44. Eskola J., and Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 18 6 (1999) 543-551
45. Shinefield H.R., Black S., Ray P., Chang I., Lewis N., Fireman B., et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 18 9 (1999) 757-763
46. Schmitt H.J., Faber J., Lorenz I., Schmöle-Thoma B., and Ahlers N. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 21 25-26 (2003) 3653-3662
47. Knuf M., Habermehl P., Cimino C., Petersen G., and Schmitt H.J. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 24 22 (2006) 4727-4736
48. Oosterhuis-Kafeja F., Beutels P., and Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 25 12 (2007) 2194-2212
49. Kayhty H., Auranen K., Nohynek H., Dagan R., and Makela H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines 5 5 (2006) 651-667
50. Trzcinski K., Thompson C., Malley R., and Lipsitch M. Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. Infect Immun 73 10 (2005) 7043-7046
51. McCool T.L., and Weiser J.N. Limited role of antibody in clearance of streptococcus pneumoniae in a murine model of colonization. Infect Immun 72 10 (2004) 5807-5813
52. Lipsitch M., Whitney C., Zell E., Kaijalainen T., Dagan R., and Malley R. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?. PLoS medicine 2 1 (2005) e15
53. Palaniappan R., Singh S., Singh U.P., Sakthivel S.K., Ades E.W., Briles D.E., et al. Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage. Infect Immun 73 2 (2005) 1006-1013
54. Malley R., Trzcinski K., Srivastava A., Thompson C., Anderson P., and Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 102 13 (2005) 4848-4853
55. Zhang Z., Clarke T.B., and Weiser J.N. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 119 7 (2009) 1899-1909
56. Jódar L., Butler J., Carlone G., Dagan R., Goldblatt D., Käyhty H., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21 23 (2003) 3265-3272
57. Yu X., Sun Y., Frasch C., Concepcion N., and Nahm M.H. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol 6 4 (1999) 519-524
58. Rajam G., Anderton J.M., Carlone G.M., Sampson J.S., and Ades E.W. Pneumococcal surface adhesin A (PsaA): a review. Crit Rev Microbiol 34 3 (2008) 131-142
59. Romero-Steiner S., Caba J., Rajam G., Langley T., Floyd A., Johnson S.E., et al. Adherence of recombinant pneumococcal surface adhesin A (rPsaA)-coated particles to human nasopharyngeal epithelial cells for the evaluation of anti-PsaA functional antibodies. Vaccine 24 16 (2006) 3224-3231
60. McCool T.L., Cate T.R., Moy G., and Weiser J.N. The immune response to pneumococcal proteins during experimental human carriage. J Exp Med 195 3 (2002) 359-365
61. Briles D.E., Novak L., Hotomi M., van Ginkel F.W., and King J. Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci. Infect Immun 73 10 (2005) 6945-6951